BRPI1008023B8 - Forma de dosagem sólida - Google Patents

Forma de dosagem sólida

Info

Publication number
BRPI1008023B8
BRPI1008023B8 BRPI1008023A BRPI1008023A BRPI1008023B8 BR PI1008023 B8 BRPI1008023 B8 BR PI1008023B8 BR PI1008023 A BRPI1008023 A BR PI1008023A BR PI1008023 A BRPI1008023 A BR PI1008023A BR PI1008023 B8 BRPI1008023 B8 BR PI1008023B8
Authority
BR
Brazil
Prior art keywords
solid dosage
dosage form
formulations
bardoxolone
particles
Prior art date
Application number
BRPI1008023A
Other languages
English (en)
Inventor
Zhang Jiang
J Meyer Colin
Original Assignee
Reata Pharmaceuticals Inc
Reata Pharmaceuticals Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1008023(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reata Pharmaceuticals Inc, Reata Pharmaceuticals Holdings Llc filed Critical Reata Pharmaceuticals Inc
Publication of BRPI1008023A2 publication Critical patent/BRPI1008023A2/pt
Publication of BRPI1008023B1 publication Critical patent/BRPI1008023B1/pt
Publication of BRPI1008023B8 publication Critical patent/BRPI1008023B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forma de Dosagem Sólida. Formulações farmacêuticas exibem um Cmax desejavelmente baixo, dentre outras propriedades, que contêm partículas de bardoxolona metil amorfa, seja em forma pura ou na forma de uma dispersão sólida, misturada com partículas de um agente de ligação hidrofílico. Essas formulações possuem a vantagem de biodisponibilidade oral mais alta, relativo para formulações com base na forma cristalina de bardoxolona metil.
BRPI1008023A 2009-02-13 2010-02-12 Forma de dosagem sólida BRPI1008023B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15260809P 2009-02-13 2009-02-13
PCT/US2010/024127 WO2010093944A2 (en) 2009-02-13 2010-02-12 Delayed release, oral dosage compositions that contain amorphous cddo-me

Publications (3)

Publication Number Publication Date
BRPI1008023A2 BRPI1008023A2 (pt) 2016-03-15
BRPI1008023B1 BRPI1008023B1 (pt) 2019-12-31
BRPI1008023B8 true BRPI1008023B8 (pt) 2023-04-11

Family

ID=42335073

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008023A BRPI1008023B8 (pt) 2009-02-13 2010-02-12 Forma de dosagem sólida

Country Status (30)

Country Link
US (2) US8747901B2 (pt)
EP (2) EP2395979B1 (pt)
JP (1) JP5775464B2 (pt)
KR (2) KR20140016441A (pt)
CN (2) CN102387789A (pt)
AU (1) AU2010213594B2 (pt)
BR (1) BRPI1008023B8 (pt)
CA (1) CA2752048C (pt)
CO (1) CO6361904A2 (pt)
CY (2) CY1119595T1 (pt)
DK (2) DK2395979T3 (pt)
EA (1) EA023652B1 (pt)
ES (2) ES2646816T3 (pt)
HK (1) HK1220130A1 (pt)
HR (2) HRP20171639T1 (pt)
HU (2) HUE044005T2 (pt)
IL (1) IL214258A (pt)
LT (2) LT2395979T (pt)
MX (1) MX2011008344A (pt)
MY (1) MY173715A (pt)
NO (1) NO2395979T3 (pt)
NZ (1) NZ594488A (pt)
PL (2) PL2395979T3 (pt)
PT (2) PT2395979T (pt)
SG (1) SG173601A1 (pt)
SI (2) SI2395979T1 (pt)
SM (2) SMT201900432T1 (pt)
TR (1) TR201909743T4 (pt)
WO (1) WO2010093944A2 (pt)
ZA (1) ZA201105630B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
BRPI0907423A2 (pt) 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
SI2395979T1 (sl) 2009-02-13 2017-12-29 Reata Pharmaceuticals, Inc. Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem
DK2558105T3 (da) 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
CN103596929B (zh) 2010-12-17 2016-10-19 里亚塔医药公司 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮
MX348862B (es) 2011-03-11 2017-07-03 Reata Pharmaceuticals Inc Derivados c4-monometil triterpenoides y sus metodos de uso.
CN103156861B (zh) * 2011-12-08 2015-11-25 陈丽梅 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
TWI623548B (zh) 2012-04-27 2018-05-11 瑞塔醫藥有限責任公司 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
JP6243428B2 (ja) 2012-09-10 2017-12-06 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
EP4736949A2 (en) 2013-08-23 2026-05-06 Reata Pharmaceuticals Holdings, LLC Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
US20170333450A1 (en) 2014-10-31 2017-11-23 The Regents Of The University Of California Compositions and methods for treating hiv-associated cognitive dysfunction
EP3256451B1 (en) 2015-02-12 2021-10-20 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
US11427533B2 (en) 2017-07-13 2022-08-30 Pliva Hrvatska D.O.O. Crystalline polymorphs of bardoxolone methyl
ES2967689T3 (es) 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
US11993574B2 (en) 2018-06-15 2024-05-28 Reata Pharmaceuticals, Inc Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
CN113164436A (zh) 2018-11-27 2021-07-23 协和麒麟株式会社 药物组合物
JP7714473B2 (ja) * 2019-05-31 2025-07-29 デナリ セラピューティクス インコーポレイテッド ピリミジニルアミノピラゾール化合物の調節放出製剤および処置方法
EP3999522B1 (en) 2019-07-19 2025-09-03 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
BR112022022599A2 (pt) 2020-05-09 2023-03-21 Reata Pharmaceuticals Holdings Llc Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
CN114558019A (zh) * 2022-03-26 2022-05-31 中国科学院昆明动物研究所 一种Rab13基因抑制剂及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
JP2008110962A (ja) * 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
JP4315182B2 (ja) * 2006-10-30 2009-08-19 ミツミ電機株式会社 カメラモジュール
WO2008111497A1 (ja) * 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
BRPI0907423A2 (pt) 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
SI2395979T1 (sl) 2009-02-13 2017-12-29 Reata Pharmaceuticals, Inc. Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem

Also Published As

Publication number Publication date
SMT201700527T1 (it) 2018-01-11
SMT201900432T1 (it) 2019-09-09
PT3254675T (pt) 2019-06-14
TR201909743T4 (tr) 2019-07-22
AU2010213594B2 (en) 2013-11-14
KR20110118721A (ko) 2011-10-31
SI2395979T1 (sl) 2017-12-29
EP3254675B1 (en) 2019-05-15
PL3254675T3 (pl) 2019-09-30
EP2395979A2 (en) 2011-12-21
PT2395979T (pt) 2017-11-16
ZA201105630B (en) 2012-04-25
KR101483203B1 (ko) 2015-01-15
IL214258A (en) 2017-06-29
CY1122066T1 (el) 2020-11-25
CO6361904A2 (es) 2012-01-20
BRPI1008023A2 (pt) 2016-03-15
MY173715A (en) 2020-02-18
KR20140016441A (ko) 2014-02-07
DK3254675T3 (da) 2019-06-24
US20140235711A1 (en) 2014-08-21
DK2395979T3 (da) 2017-11-27
SG173601A1 (en) 2011-09-29
WO2010093944A2 (en) 2010-08-19
WO2010093944A3 (en) 2011-08-11
HRP20171639T1 (hr) 2017-12-15
SI3254675T1 (sl) 2019-08-30
US20120022156A1 (en) 2012-01-26
US9155721B2 (en) 2015-10-13
JP5775464B2 (ja) 2015-09-09
HUE035013T2 (en) 2018-05-02
EA023652B1 (ru) 2016-06-30
ES2646816T3 (es) 2017-12-18
ES2731601T3 (es) 2019-11-18
NZ594488A (en) 2013-10-25
US8747901B2 (en) 2014-06-10
IL214258A0 (en) 2011-09-27
BRPI1008023B1 (pt) 2019-12-31
EA201190092A1 (ru) 2012-02-28
LT2395979T (lt) 2017-12-11
CN102387789A (zh) 2012-03-21
AU2010213594A1 (en) 2011-08-18
EP3254675A1 (en) 2017-12-13
JP2012518008A (ja) 2012-08-09
CN105232471A (zh) 2016-01-13
CY1119595T1 (el) 2018-03-07
NO2395979T3 (pt) 2018-01-20
MX2011008344A (es) 2011-09-29
CA2752048C (en) 2014-11-25
HRP20191092T1 (hr) 2019-11-29
EP2395979B1 (en) 2017-08-23
CA2752048A1 (en) 2010-08-19
PL2395979T3 (pl) 2018-02-28
HUE044005T2 (hu) 2019-09-30
LT3254675T (lt) 2019-06-25
HK1220130A1 (zh) 2017-04-28

Similar Documents

Publication Publication Date Title
BRPI1008023B8 (pt) Forma de dosagem sólida
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
MX2010005346A (es) Composiciones farmaceuticas.
BRPI0819936A2 (pt) Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação.
WO2011110854A3 (en) The use of amisulpride as an anti-emetic
BR112013004016A2 (pt) formulações á base de nalbufina e as respectivas utilizações
BRPI0817503B8 (pt) derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
EA201001334A1 (ru) Твёрдый препарат гидрохлорида карипразина для перорального введения
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
BR212012031500U2 (pt) composições sólidas
BR112015000320A2 (pt) composições farmacêuticas dissuasivas de abuso, de liberação prolongada
CR10270A (es) Medicamentos que contienen fluoroquinolonas
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
NI201000189A (es) Formulación de medicamento sólido con liberación retardadas.
MX2012013021A (es) Formulaciones resistentes a alcohol.
PT103884A (pt) Composições de libertação prolongada e métodos para a sua preparação
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
MY164204A (en) Formulations comprising polyethylene glycol
EP2497464A3 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
CY1120050T1 (el) Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων
BR112014023092A8 (pt) Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
WO2015079415A9 (en) Amorphous cobicistat solid dispersion
AR059081A1 (es) Composicion farmaceutica estable de carisoprodol y meloxicam
ES2468665B1 (es) Composición farmacéutica de sulfato de condroitina y celecoxib
BR112014032033A2 (pt) formulações para a preparação de comprimidos de liberação imediata para administração oral contendo uma baixa dosagem de mifepristona, comprimidos desse modo obtidos e seu processo de preparação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: REATA PHARMACEUTICALS HOLDINGS, LLC (US)